Hem

Press release from Companies

Publicerat: 2022-12-07 16:00:00

Cessatech A/S: CESSATECH’S COMPENSATION ISSUE IN CONNECTION WITH THE RECENT RIGHTS ISSUE HAS BEEN REGISTERED

Copenhagen, Denmark, December 7, 2022 – On November 24, 2022, Cessatech A/S ("Cessatech" or the "Company") announced the resolution of the board of directors to issue in total 56,875 compensation units to certain guarantee underwriters in connection with Cessatech’s recently completed rights issue. Each compensation unit consists of 6 new shares and 3 warrants of series TO2 (corresponding to 341,250 new shares and 170,625 warrants of series TO2). Today, the capital increase has been completed and registered with the Danish Business Authority (dk: "Erhvervsstyrelsen").

With reference to the company announcement of November 24, 2022, Cessatech hereby informs that the capital increase with a nominal value of DKK 68,250 (corresponding to 341,250 new shares of a nominal value of DKK 0.20 each) has been completed and registered with the Danish Business Authority.

After the registration of the capital increase, Cessatech has a registered share capital of a nominal value of DKK 2,757,751 (corresponding to 13,788,755 shares in total each with a nominal value of DKK 0.20).

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development.

Läs mer hos Cision
Läs mer om Cessatech A/S

Prenumeration